Janux Therapeutics (JANX) Non-cash Items (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Non-cash Items data on file, last reported at $6.9 million in Q1 2026.

• Non-cash Items for Q1 2026 came in at $6.9 million, up 10.37% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (up 10.37% YoY), and the FY2025 annual result was $6.7 million, up 23.64% from the prior year.
• Non-cash Items retreated to $6.9 million in Q1 2026 per JANX's latest filing, from $29.6 million in the prior quarter.
• Over five years, Non-cash Items peaked at $361.6 million in Q4 2024 and troughed at $5.0 million in Q2 2022.
• A 5-year average of $47.5 million and a median of $6.8 million in 2025 frame the typical range for Non-cash Items.
• The sharpest annual moves came in 2024 and 2025: Non-cash Items surged 4686.87% in 2024, then plunged 97.54% in 2025.
• A 5-year view of Non-cash Items shows it stood at $29.8 million in 2022, then plunged by 43.86% to $16.7 million in 2023, then soared by 2060.97% to $361.6 million in 2024, then slumped by 91.82% to $29.6 million in 2025, then sank by 76.75% to $6.9 million in 2026.
• Business Quant data shows JANX's Non-cash Items at $6.9 million in Q1 2026, $29.6 million in Q4 2025, and $6.8 million in Q3 2025.